Unity Biotechnology (LTS:0YC0) Total Equity: $-0.21 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0YC0 Unity Biotechnology Inc LTS:0YC0
25 GF Score
Price $0.06
View Full Analysis

What is Unity Biotechnology Total Equity?

Unity Biotechnology LTS:0YC0 25 Total Equity is $-0.21 Mil as of Mar. 2025. GuruFocus rates LTS:0YC0 with a GF Score™ of 25/100.

Unity Biotechnology's total equity for the quarter that ended in Mar. 2025 was $-0.21 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Unity Biotechnology Total Equity Historical Data

* Premium members only.

The historical data trend for Unity Biotechnology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unity Biotechnology Total Equity Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only 82.88 59.57 56.08 28.40 6.49

Unity Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.99 19.75 14.14 6.49 -0.21
LTS:0YC0
25GF Score
Unity Biotechnology Inc LTS:0YC0
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unity Biotechnology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Unity Biotechnology's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=37.662-31.168
=6.49

Unity Biotechnology's Total Equity for the quarter that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=30.347-30.552
=-0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-0.21 Mil mean?
Unity Biotechnology (LTS:0YC0) has a Total Equity of $-0.21 Mil as of Mar. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Unity Biotechnology and its competitors.
Is Unity Biotechnology's Total Equity too high?
Unity Biotechnology's current Total Equity is $-0.21 Mil. Overall, Unity Biotechnology has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Unity Biotechnology's Total Equity compare to ADTX and HEPA?
Unity Biotechnology's Total Equity of $-0.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Unity Biotechnology and its competitors. Unity Biotechnology's current Total Equity is $-0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (LTS:0YC0) has a current Total Equity of $-0.21 Mil. The current Total Equity is $-0.21 Mil. Unity Biotechnology's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Unity Biotechnology (LTS:0YC0), the current Total Equity is $-0.21 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unity Biotechnology Business Description

Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
25GF Score

Get the complete analysis for LTS:0YC0

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.06
Price